Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-06-02

FDA Approved: OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE — Supplemental Application (Par Health USA, LLC)

View source ↗

Summary

The FDA approved a supplemental application for a generic fixed-dose combination of olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide for hyper…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Amlodipine besylate (amlodipine besylate)
  • HYDROCHLOROTHIAZIDE (hydrochlorothiazide)
  • OLMESARTAN MEDOXOMIL (olmesartan medoxomil)

Snippet

SUPPL AP for OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE (OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE)